An abuse liability assessment was conducted to determine the abuse potential and pharmacokinetics of extended-release vs immediate-release oxycodone.
Abuse-deterrent extended-release oxycodone (Xtampza® ER; Collegium Pharmaceutical) provided adequate pain relief for patients with chronic low back pain who were previously receiving immediate-release oxycodone.
Abuse-deterrent opioid formulations may not be the most effective solution to the opioid crisis, according to an editorial published in the New England Journal of Medicine.
Clinical Pain Advisor Articles
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Wearable Device Cleared for Use During Opioid Detoxification
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Opioid-Related Adverse Events Common After Invasive Procedures
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Zoledronic Acid May Not Improve Knee Osteoarthritis-Related Pain, Function Long-Term
- Sleep Quality in Chronic Tension-Type Headaches